SCHEMBL4848938

SCHEMBL4848938

N#Cc1c(N2CCN(C(=O)c3cccs3)CC2)c2cccnc2n(C2CCCCC2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 3/20 0.40
MAPK1 P28482 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
THRB P10828 1/20 0.39
GAA P10253 3/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ELANE P08246 1/20 0.39
KCNA5 P22460 1/20 0.39
DCTPP1 Q9H773 1/20 0.39
AXL P30530 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14438366 0.86 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAMAPK1KMT2A
SCHEMBL4851476 0.85 ALDH1A1 (0.52) ALDH1A1LMNAMAPK1KMT2AMEN1
SCHEMBL14349934 0.85 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAMAPK1KMT2A
SCHEMBL4854607 0.85 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2LMNAMAPK1KMT2A
SCHEMBL4858148 0.83 ALDH1A1 (0.49) ALDH1A1LMNAMAPK1KMT2AMEN1
SCHEMBL14195251 0.82 ALDH1A1 (0.48) ALDH1A1LMNAMAPK1KMT2AMEN1
SCHEMBL4856567 0.82 ALDH1A1 (0.48) ALDH1A1LMNAMAPK1KMT2AMEN1
SCHEMBL27651866 0.81 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAMAPK1KDM4E
SCHEMBL4856561 0.81 ALDH1A1 (0.48) ALDH1A1LMNAMAPK1KMT2AMEN1
SCHEMBL4850922 0.81 HTT (0.49) ALDH1A1SMN1; SMN2LMNAMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361760-B2 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases AVANIR PHARMACEUTICALS (US) 2008-04-22 US disclosed
US-20070191388-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2007-08-16 US disclosed
EP-1656376-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES Avanir Pharmaceuticals (US) 2006-05-17 EP disclosed
US-20050124604-A1 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases AVANIR PHARMACEUTICALS, INC. 2005-06-09 US disclosed
WO-2005021546-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191388-A1 SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES MIF, MSR1, SLC11A2 ALDH1A1 2477/4885SMN1; SMN2 2412/4885LMNA 673/4885
US-20050124604-A1 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases MIF, MSR1, SLC11A2 ALDH1A1 2477/4885SMN1; SMN2 2412/4885LMNA 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.